Sacubitril/Valsartan 沙库必曲/缬沙坦; LCZ696|cas:936623-90-4|西域试剂

Sacubitril/Valsartan 沙库必曲/缬沙坦; LCZ696,99.99%

产品编号：Bellancom-18204A| CAS NO：936623-90-4| 分子式：C₄₈H₅₅N₆Na₃O₈.2.5H₂O| 分子量：957.99

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-18204A	￥1100.00	杭州北京（现货）
Bellancom-18204A	￥1550.00	杭州北京（现货）
Bellancom-18204A	￥3980.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Sacubitril/Valsartan 沙库必曲/缬沙坦; LCZ696

产品介绍

Sacubitril/Valsartan (LCZ696) 是由 Valsartan (an ARB) 和 Sacubitril (AHU377) 组成，摩尔比为 1:1，是一种首创的，口服有效的血管紧张素受体-脑啡肽酶 (ARN) 双抑制剂，用于研究高血压和心力衰竭。Sacubitril/Valsartan 可通过抑制炎症、氧化应激和细胞凋亡来改善糖尿性心肌病。

生物活性

Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis^[4].

体外研究

Sacubitril/Valsartan (LCZ696; 1-30 µM; 0.5 hours) inhibits HG-treated H9C2 cells apoptosis in an experimental model of Diabetic cardiomyopathy (DCM)^[4].
Sacubitril/Valsartan (1-30 µM; 0.5 hours) increases the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2 in HG-treated H9C2 cells^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[4]

Cell Line:	HG-treated H9C2 cells
Concentration:	1, 10, or 30 µM
Incubation Time:	0.5 hours
Result:	Inhibited HG-treated H9C2 cells apoptosis.

Western Blot Analysis^[4]

Cell Line:	HG-treated H9C2 cells
Concentration:	1, 10, or 30 µM
Incubation Time:	0.5 hours
Result:	Increased the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2.

体内研究
(In Vivo)

Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight)
Dosage:	68 mg/kg
Administration:	Perorally; for 4 weeks
Result:	Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone.

体内研究

Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight)
Dosage:	68 mg/kg
Administration:	Perorally; for 4 weeks
Result:	Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone.

体内研究

Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight)
Dosage:	68 mg/kg
Administration:	Perorally; for 4 weeks
Result:	Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (104.39 mM)

H₂O : ≥ 50 mg/mL (52.19 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.0439 mL	5.2193 mL	10.4385 mL
5 mM	0.2088 mL	1.0439 mL	2.0877 mL
10 mM	0.1044 mL	0.5219 mL	1.0439 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (104.39 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.61 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.61 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。